BioStem Technologies, Inc. (OTCMKTS:BSEM – Free Report) – Equities research analysts at Zacks Small Cap boosted their Q3 2024 earnings per share (EPS) estimates for BioStem Technologies in a report released on Thursday, October 17th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings per share of $0.36 for the quarter, up from their previous forecast of $0.31. The consensus estimate for BioStem Technologies’ current full-year earnings is $1.13 per share. Zacks Small Cap also issued estimates for BioStem Technologies’ Q4 2024 earnings at $0.38 EPS.
BioStem Technologies Stock Down 4.3 %
Shares of OTCMKTS BSEM opened at 11.95 on Friday. BioStem Technologies has a twelve month low of 2.26 and a twelve month high of 15.50. The stock has a market cap of $194.64 million, a price-to-earnings ratio of 30.64 and a beta of 0.05. The company’s fifty day moving average is 10.84 and its 200-day moving average is 9.81.
BioStem Technologies Company Profile
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Recommended Stories
- Five stocks we like better than BioStem Technologies
- What Do S&P 500 Stocks Tell Investors About the Market?
- Survey Reveals: America’s Most Coveted Businesses in 2024
- CD Calculator: Certificate of Deposit Calculator
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- 3 Best Fintech Stocks for a Portfolio Boost
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for BioStem Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioStem Technologies and related companies with MarketBeat.com's FREE daily email newsletter.